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A B S T R A C T
Antimicrobial resistance (AMR) in populations experiencing war has yet to be addressed, despite the
abundance of contemporary conflicts and the protracted nature of twenty-first century wars, in
combination with growing global concern over conflict-associated bacterial pathogens. The example of
the Syrian conflict is used to explore the feasibility of using existing global policies on AMR in conditions
of extreme conflict. The available literature on AMR and prescribing behaviour in Syria before and since
the onset of the conflict in March 2011 was identified. Overall, there is a paucity of rigorous data before
and since the onset of conflict in Syria to contextualize the burden of AMR. However, post onset of the
conflict, an increasing number of studies conducted in neighbouring countries and Europe have reported
AMR in Syrian refugees. High rates of multidrug resistance, particularly Gram-negative organisms, have
been noted amongst Syrian refugees when compared with local populations. Conflict impedes many of
the safeguards against AMR, creates new drivers, and exacerbates existing ones. Given the apparently
high rates of AMR in Syria, in neighbouring countries hosting refugees, and in European countries
providing asylum, this requires the World Health Organization and other global health institutions to
address the causes, costs, and future considerations of conflict-related AMR as an issue of global
governance.
© 2018 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Despite the proliferation of contemporary conflicts, the
emergence of antimicrobial resistance (AMR) in settings of war
and distressed migration has been neglected. This has been of
particular concern in Syria where the protracted and increasingly
destructive conflict has also been a driver of large-scale population
movements both regionally and in Europe. Since 2012, the conflict
has become the leading cause of death and injury in Syria. In the
absence of accurate recent figures, it is estimated, as of the end of
2015, that 470 000 have been killed and 1.9 million injured (Syrian
Center for Policy Research, 2018). With high rates of injury, the
potential for infection is exacerbated by the crowded and often
unsanitary conditions in health facilities, combined with the
nature of injuries produced by heavy weaponry.
The destruction of health facilities, the exodus or death of
healthcare workers, and the increasing fragmentation of Syria’s
health system have all contributed to the myriad of challenges in
addressing AMR (Fouad et al., 2017). By April 2017, only 56 out of
111 public hospitals were still offering services (WHO, 2018), while
it has been estimated that over 70% of all health professionals have
left the country since the conflict began. Of the 6.4 million
internally displaced persons (IDPs) estimated by the United
Nations Office for the Coordination of Humanitarian Affairs
(OCHA), more than one million live in unhygienic conditions in
overcrowded camps and collective shelters, at increased risk of
typhoid, hepatitis, cholera, polio, and cutaneous leishmaniasis,
among other infectious diseases (Ismail et al., 2016).
Under conditions of conflict, many of the safeguards against
AMR are broken and drivers are accentuated; these include
damaged health and sanitation infrastructure, disrupted medical
supplies, the exodus of expert and trained health professionals, and
increasing exposure in compromised healthcare settings. War
further disrupts the political and regulatory bodies that often lead,
monitor, and enforce policies that tackle the drivers of AMR. This
first part of a two-part series presents a review and analysis of the
literature on what is known about AMR in the Syrian conflict. The
second part explores the pre-existing drivers of AMR in Syria and
those that have occurred since the onset of conflict; recommen-
dations on how these can be addressed are also made.
Evidence of AMR in the Syrian context
Rigorous studies addressing microbiology or AMR in Syria,
either before or since the onset of the conflict in March 2011, are
scarce. Published studies have often been from a single centre and
have presented limited data of variable quality. Functioning
laboratories are restricted to major cities such as Damascus,
Aleppo, and Lattakia, mainly in government-controlled areas
(GCAs). Whether private or hospital-based, all laboratories close
between Thursday afternoon and Sunday morning. As there is no
on-call service, laboratory services are unavailable for 2.5 days
each week. These laboratories are inaccessible to health workers
serving the outskirts of these cities and rural areas in GCAs, in
addition to the estimated 10 million people living in non-government-controlled areas (NGCAs), served by six laboratories
(verbal communication) (Plate 1 ).
There are two parallel systems of surveillance. From Damascus,
the Syrian Arab Republic Ministry of Health with the support of the
World Health Organization (WHO) collects reports of notifiable
diseases through the Early Warning and Response System
(EWARS), but without laboratory testing of samples or contact
tracing. Operating from Gaziantep in southern Turkey, the Early
Warning and Response Network (EWARN) system is hampered by
the paucity of laboratory services and the absence of local referral
laboratories for verification and typing. Data from these systems
may not be reliable in this context, nor generalizable across the
country (Ismail et al., 2016; Sparrow et al., 2016). Neither system
requires reporting on AMR, nosocomial infections, or response to
therapy. Both systems are hampered by limited surveillance in
governorates under the control of ISIS (Raqqa and Deir Ezzor) and
the lack of quality control services and access to accredited referral
laboratories. In GCAs this requires shipping of samples to Egypt; in
NGCAs this requires cross-border transport to Turkey or Jordan,
subject to permission from the relevant ministry of health. Both
circumstances are challenging given the insecurity, difficulty in
transporting specimens under controlled temperature conditions,
and restricted access across borders.
A review of the scientific literature describing AMR amongst
Syrians who remain in Syria and those who are refugees either in
the region (Jordan, Lebanon, Turkey) or in Europe was performed
to accurately describe the current literature on AMR in the Syrian
conflict. The search methods are given in the Appendix A. Table 1
summarizes studies addressing AMR before and after the onset of
the conflict, including all published articles relating to refugees or
Syrians inside Syria.
Evidence of AMR in the Syrian context: pre-conflict
Before the conflict, several reports suggested the widespread
availability of antibiotics through pharmacies without safeguards
and/or poor knowledge amongst recipients of the risks associated
with injudicious antibiotic use (Barah and Gonçalves, 2010).
Anecdotally, extensive antibiotic overuse and antimicrobial failure
were common. Limited evidence documenting the existence and
prevalence of AMR was found in the perusal of the scientific
literature. Studies identified were notable for their small size,
inconsistent reporting, and questionable methodology,
compromising the potential to identify trends or draw conclusions
concerning AMR. Most studies were reported from the cities of
Damascus and Aleppo, limiting generalization across and to other
governorates.
Seven studies describing antibiotic susceptibility amongst
different isolates were found (Table 1). The majority focused on
specific bacteria including Acinetobacter baumannii, Streptococcus
pneumoniae, and Brucella melitensis (Hamzeh et al., 2012;
Turkmani et al., 2006; Obeid and Obeid, 2005). Hamzeh and
colleagues reported high levels of AMR in 260 unique patients with
A. baumannii infections from Aleppo in 2008–2011 (Hamzeh et al.,
2012). Resistance to imipenem and meropenem (carbapenems)
Plate 1. This is a map of Syria which shows the location of the major cities, Damascus, Lattakia and Aleppo where the main functioning laboratories remain.
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piperacillin–tazobactam (penicillin-beta-lactamase) 87%, amika-
cin (aminoglycoside) 78%, and to co-trimoxazole (sulfonamide)
74%. Resistance to third- and fourth-generation cephalosporins
was also high, with ceftazidime resistance reported at 80.6% and
cefepime at 84.7%. Colistin remained active with only 7% reported
resistance. The main drawback of this study was the use of an
automated system for species identification, bearing in mind that
these systems are unable to precisely distinguish isolates from the
A. baumannii–Acinetobacter calcoaceticus complex to the species
level. Keddo et al. reported that 25% of Klebsiella pneumoniae
isolates amongst children with recurrent tonsillitis were carba-
penem-resistant (Keddo and Al-Omari, 2012). With regards to
Gram-positive isolates, the most recent study found was con-
ducted in 2005: Obeid and colleagues reported high rates of
resistance to penicillin (64%) and trimethoprim–sulfamethoxazole
(48%) in 25 isolates of S. pneumoniae from cerebrospinal fluid
samples, but found no resistance to cephalosporins (including
cefotaxime and ceftriaxone), often used as first-line therapy for
bacterial meningitis (Obeid and Obeid, 2005).
Although these reports describe small numbers, they raise
concern regarding the high rates of AMR reported. The high
proportion of carbapenem-resistant Gram-negatives is alarming
given that carbapenems are used as broad-spectrum or salvage
therapy following failure of empiric therapy. The percentage of
penicillin-resistant S. pneumoniae is troubling, as overuse of
antibiotics in the treatment of viral illness is a driver of penicillin
resistance in this isolate.
Evidence of AMR in the Syrian context: since the onset of the
conflict in 2011
Since the first use of armed force and subsequent expansion of
violence, data on the availability and efficacy of antimicrobial therapy
within Syria have become increasingly limited. Six studies from inside
Syria since late 2011 have reported concerns over the increasingburdenofresistantGram-negativeinfectionsandmethicillin-resistant
Staphylococcus aureus (MRSA), four of these being focused on Aleppo
(Alheib et al., 2015; Mahfoud et al., 2015; Al-Assil et al., 2013; Tabana
et al., 2015). It is notable that few datasets from within Syria have
reported onwar-related injuries and their infectious complications;
this is likely driven by several factors including political sensitivities
and the overwhelmed health systems.
Studies of resistance from inside Syria on specific isolates have
reported high levels of AMR. Zain and colleagues examined 236
Escherichia coli isolates and found 26% of these to be extended-
spectrum beta-lactamase (ESBL) producers (Baaity et al., 2017).
Alheib and colleagues examined 123 ESBL-producing E. coli and K.
pneumoniae specimens in 2015 and found 66% of these isolates to
be phenotypically resistant to ciprofloxacin (Alheib et al., 2015).
Mahfoud and colleagues tested 177 Pseudomonas aeruginosa
urinary and lower respiratory isolates from patients in three
intensive care units in Aleppo and showed significant resistance to
common anti-pseudomonal agents (piperacillin–tazobactam: 46%;
meropenem: 41%; ceftazidime 73%) with colistin as the most
reliable antibiotic (11% resistance) (Mahfoud et al., 2015). Al-Assil
reviewed 104 patients with positive urine samples to understand
the risk factors for the development of ESBL infections and isolated
ESBL E. coli in 52% of cases (Al-Assil et al., 2013). Co-resistance to
other antibiotics was found in 82% of cases. Risk factors identified
as increasing the risk of ESBL acquisition in that study included
older age (>52 years), hospitalization, urinary catheterization, and
previous exposure to third-generation cephalosporins or quino-
lone antibiotics (Al-Assil et al., 2013).
Of the few large regional studies, a recent retrospective study in
Lebanon analysing 55 594 Gram-negative isolates between 2011
and 2013 reported ESBL rates amongst E. coli and Klebsiella spp of
32.3% and 29.2%, respectively (Chamoun et al., 2016). Lebanon and
Jordan, countries neighbouring Syria and hosting an estimated
total of 1.7 million refugees, both reported the emergence of
multidrug-resistant (MDR) Gram-negative infections complicating
war-related injuries (Teicher et al., 2014; Abbara et al., 2017; Rafei
Table 1
Characteristics of key studies: divided into pre and post onset of the conflict in Syria, regional studies including Syrian refugees, and other studies describing Syrian refugees.
Group (year of
publication)
Year Location Study description Sample Key findings
Pre-conflict
Al-Omar (2005) 2004 Misiaf, Syria Prospective culture of urine samples
from all patients in the community
127 positive urine
samples
 68.6% of isolates were Enterobacter-
iaceae
 30.6% were Gram-positive (22.8% S.
aureus)
 Overall resistance reported at: 69%
ampicillin, 55% TMP–SMX, 37%
amoxicillin–clavulanate, 35% ofloxa-
cin
Obeid and Obeid (2005) Sep 2003 to
May 2004
Damascus, Syria S. pneumoniae from CSF samples;
susceptibility of strains using disc
diffusion methods (NCCLS breakpoints)
25 isolates  Reported resistance: 64% were re-
sistant to penicillin, 48% to TMP–
SMX,16% to erythromycin, and 16% to
tetracycline
 None resistant to ceftriaxone, cefo-
taxime, amoxicillin–clavulanate
Al-Qwaret et al. (2010) 2010 Damascus, Syria Prospective cohort study of aerobic
organisms isolated from diabetic foot




 61% of S. aureus isolates were MRSA
 N CPE/CRO identified
Al-Qwaret et al. (2010) 2012 Damascus, Syria Review of all aerobic bacterial
conjunctivitis with antibiotic
susceptibilities
51 patients  High levels of susceptibility to first-
and second-line agents reported
Keddo and Al-Omari
(2012)
2012 Damascus Syria Paediatric recurrent tonsillitis cases
that underwent tonsillectomy
Review of aerobic isolates from tonsil
core culture
80 patients  25% of the K. pneumoniae isolates
were carbapenem-resistant
 15% of E. coli were also imipenem-
resistant
Hamzeh et al. (2012) 2008–2011 Aleppo, Syria Retrospective review of A. baumannii
isolates
260 patients with 260
isolates tested
 Resistance to specific antibiotics:
65% imipenem, 87% piperacillin–
tazobactam, 78% amikacin, 81% cip-
rofloxacin, 74% co-trimoxazole, 7%
colistin
Turkmani et al. (2006) 1995–2005 Eastern
Mediterranean
Isolates of B. melitensis from animals in
Syria
5 isolates  Highly susceptible to most tested
antibiotics
Post commencement of the conflict – Syria
Al-Kadrou et al. (2013) 2013 Damascus, Syria Aerobic bacterial infections in burns
patients managed within a Syrian
government hospital
109 isolates from 53
samples
 No polymyxin resistance in Gram-
negatives identified
Tabana et al. (2015) 2015 Aleppo, Syria Laboratory evaluation of prevalence of
PMQR genes at Aleppo University
123 ESBL-producing
isolates of E. coli and K.
pneumoniae
Al-Assil et al. (2013) 2011 Aleppo, Syria Three hospitals in Aleppo; 75 patients
with UTIs
75 patients with UTIs
caused by
trimethoprim-resistant
E. coli; 104 unique
isolates
 96% susceptible to nitrofurantoin
 Reduced susceptibility to:
amoxicillin–clavulanate 43%, 3/4
GNB to cephalosporins 50–60%,
piperacillin–tazobactam 66%, tetra-
cyclines 44%, TMP–SMX 20%
Alheib et al. (2015) 2015 Aleppo, Syria PMQR genes among ESBL E. coli and K.
pneumoniae
123 isolates  66% of ESBL-positive isolates were
resistant to ciprofloxacin
 83% of E. coli compared to 87% of K.
pneumoniae harboured PMQR genes,
but this did not necessarily confer
phenotypic resistance
Mahfoud et al. (2015) 2011–12 Aleppo, Syria Three major hospitals in Aleppo
Lower respiratory tract and urine
samples with nosocomial infections




 59 female/118 male
 Samples: 138 lower respiratory tract
and 39 urinary
 Selected susceptibility: piperacillin–
tazobactam 54.5%, amikacin 42.8%,
ceftazidime 28.6%, meropenem
59.1%, imipenem 56.1%, colistin 89.1%
Nofal (2016) 2016 Damascus, Syria Retrospective review of species and
sensitivities of otitis media cases
87 patients, 49 isolates  52% male, 48% female
 K. pneumoniae (n = 3): 100% sensitive
to imipenem and levofloxacin
 S. aureus (n = 16): 100% sensitive to
imipenem
Al-Assil et al. (2013) 2011 Aleppo, Syria Three hospitals in Aleppo
Risk factors for ESBL infections
104 patients with
positive urine samples
 MDR E. coli 63%
 ESBL E. coli 52%




Year Location Study description Sample Key findings
assessed by multivariate regression
analysis
 Levels of co-resistance high in ESBLs
(82%)
 Age >52 years, hospitalization, uri-
nary catheters, prior third-genera-
tion cephalosporin use, and previous
quinolone therapy were all associ-
ated with ESBLs in this study
Baaity et al. (2017) Latakia, Syria Al-Assad Teaching
Antibiotic susceptibility and ESBL
production by disc diffusion using CLSI/
EUCAST
236 E. coli isolates  32% of the E. coli isolates were MDR
and 26% were ESBL-producers
Post commencement of the conflict – outside Syria
Teicher et al. (2014) 2011–13 Amman Jordan Médecins Sans Frontières surgical
project managing
MDR defined as: (1) ESBL-expressing
Enterobacteriaceae; (2) P. aeruginosa
and A. baumannii isolates resistant to at
least one agent in three antimicrobial







 Age 26 years (IQR 22–34 years); 98%
male
 Injury to admission approximately 5
months (IQR 1.2–8.1 months): gun-
shot wounds n = 31, explosion
wounds n = 20
 45 of these patients had at least one
organism, with 69% (31/45) MDR
organisms: P. aeruginosa (10/31), E.
coli (5/8), carbapenem-resistant A.
baumannii (4/5), MRSA (7/17)
Kassem et al. (2017) 2013–2016 Israel Microbiological surveillance screening
of severely ill or injured Syrian children
Screened for: ESBL, CRE, MRSA, MDR A.
baumannii, and VRE
128 children  MDR carriage found in 83%, with
NDM CRE most prevalent
 24/128 had MDR infections (90%
were wounded): ESBL 66%, MDR A.
baumannii 20%, CRE 15%
Angeletti et al. (2016) 2016 Italy Microbiological surveillance using
rectal, pharyngeal, and nasal swabs
48 refugees  High rates of Gram-negative non-
lactose-fermenting organisms such
as Pseudomonas and Aeromonas spe-
cies, with 5 carbapenem-resistant
isolates
 No CRE
 24% (6/25) of S. aureus isolates were
methicillin-resistant
Bhalla et al. (2016) 2016 Amman, Jordan Observational study at the Médecins
sans Frontières surgical programme
hospital managing chronic trauma-
related infections colonized or infected
with AMR organisms
NA NA
Abbara et al. (2017) 2015 Amman, Jordan Microbiological samples from infected
injuries (bone and soft tissue) amongst
injured Syrian refugees
75 patients  20% had osteomyelitis, 53% had
prosthetic material
 30 bacterial isolates of which 97%
were GNB






Screening of asylum seekers for MDROs




 31% colonized with an MDRO: 7.7%
with MRSA; 20% ESBL (20 E. coli, 4 K.
pneumoniae, 1 M. morganii, and 1 E.
cloacae)
 10% resistant to fluoroquinolones
 No carbapenemases
Reinheimer et al. (2016) 2015 Germany Microbiological surveillance screening
of patients admitted to Frankfurt
hospital for MDROs, for GNB (ESBL and
A. baumannii), and MRSA
143 refugees, including
47 (43%) from Syria, 29
from Afghanistan, 14
from Somalia
 60.8% colonized with MDR GNB in
Refugee population compared to
16.8% in the general population
 ESBL E. coli and K. pneumoniae were
significantly more common (23.8%
vs. 4.9% and 4.2% vs. 0.8%)
 1 CRE and 2 carbapenem-resistant A.
baumannii
 MRSA 5.6% vs. 1.2% in the general
population
Heudorf et al. (2016) 2015 Frankfurt, Main,
Germany
Microbiological surveillance screening
of unaccompanied minors (aged
<18 years) screened for MDR
Enterobacteriaceae in stool samples
119 individuals, 7
Syrians
 Total: 35% had ESBL Enterobacteria-
ceae, including 8% GNB resistant to
three antibiotic groups
 Syrians: 3 had ESBL Enterobacteria-
ceae; none had MDR
30 A. Abbara et al. / International Journal of Infectious Diseases 75 (2018) 26–33
Tenenbaum et al.
(2016)
2015–2016 Germany Retrospective observational study of
screening of paediatric refugee patients
admitted to hospital
325 patients  MDR detected in 33.8%
 110 of 113 samples GNB
 87 MDR GNB/ESBL
 22 MRSA
 1 VRE
Heydari et al. (2015) 2014 Turkey Microbiological surveillance screening
of all A. baumannii resistant to
carbapenems collected over the year




 1 isolate of 2 from a Syrian refugee
admitted to ICU with acute renal failure
and gastritis
Peretz et al. (2014) 2014 Galilee Medical
Centre, Israel
Microbiological surveillance screening
of Syrians admitted to hospital
Screened for: ESBL, CRE, MRSA, MDR A.
baumannii, and VRE
27 children and 60
adults
 Children: 21 isolates of MDROs in 19/
27 patients; 20/21 ESBL Enterobac-
teriaceae; MRSA = 1/21
 Adults: 28/60 carriers; 5 patients,
CRE (2  NDM); 11 patients, MRSA; 5
A. baumannii; 7 ESBL
Rafei et al. (2014) 2012 Lebanon Syrians admitted to Lebanese hospitals
Carbapenem-resistant A. baumannii
isolates investigated using PCR to
identify OXA and NDM producing
organisms
4 patients with war
wounds
 All 4 had carbapenem-resistant A.
baumannii identified as carrying the
bla-NDM-1 gene
 These organisms all had phenotypic
susceptibility to aminoglycosides,
colistin, and tigecycline
Rafei et al. (2015) 2011–13 Lebanon Review of isolates from Lebanese and
Syrian wounded; respiratory, wound,
urine, catheters, and blood isolates
116 isolates  90 male, 26 female
 70/116 (60%) had carbapenem-re-
sistant phenotype (including NDM-1
and OXA-23)
 Syrian refugees had a greater number
of carbapenem-resistant A. bauman-
nii (74% vs. 47%)
A. baumannii, Acinetobacter baumannii; AMR, antimicrobial-resistant; B. melitensis, Brucella melitensis; CLSI, Clinical and Laboratory Standards Institute; CPE, carbapenemase-
producing Enterobacteriaceae; CRE, carbapenem-resistant Enterobacteriaceae; CRO, ; CSF, cerebrospinal fluid; E. coli, Escherichia coli; E. cloacae, Enterobacter cloacae; ESBL,
extended-spectrum beta-lactamase; EUCAST, European Committee on Antimicrobial Susceptibility Testing; GNB, Gram-negative bacilli; ICU, intensive care unit; IQR,
interquartile range; K. pneumoniae, Klebsiella pneumoniae; MDR, multidrug-resistant; MDRO, multidrug-resistant organism; M. morganii, Morganella morganii; MRSA,
methicillin-resistant Staphylococcus aureus; NA, no; NCCLS, National Committee for Clinical Laboratory Standards; NDM, New Delhi metallo-beta-lactamase; OXA, ; P.
aeruginosa, Pseudomonas aeruginosa; PMQR, plasmid-mediated quinolone resistance; S. aureus, Staphylococcus aureus; S. pneumoniae, Streptococcus pneumoniae; TMP–SMX,
trimethoprim–sulfamethoxazole; UTI, urinary tract infection; VRE, vancomycin-resistant enterococci.
A. Abbara et al. / International Journal of Infectious Diseases 75 (2018) 26–33 31et al., 2015; Rafei et al., 2014). In 2014, Teicher and colleagues
reported on the experience of a Médecins sans Frontières (MSF)-
led surgical management project in Amman, Jordan (Teicher et al.,
2014). A cohort of 61 young men (median age 26 years) presented
to the hospital with clinically infected chronic war wounds (injury
to presentation time median 5 months, interquartile range 1.2–8.1
months). Gunshot (31 patients) and explosion-related (20
patients) wounds were the most common injuries. Of the 61
patients, 45 had at least one positive culture, with 69% (31/45) of
isolates being MDR. Although numbers were small, high rates of
carbapenem-resistant A. baumannii (80%; 4/5), ESBL-producing E.
coli (62%; 5/8), and MRSA (41%; 7/17) were isolated. Similar rates of
MDR organisms have been reported related to war injuries (Teicher
et al., 2014; Abbara et al., 2017), and refugees have been reported to
have significantly higher rates of carbapenem-resistant A. bau-
mannii (Rafei et al., 2014). No data are available from Turkey, which
hosts nearly three million Syrian refugees.
A more robust evidence base of AMR and the Syrian refugee
crisis has come from an increasing number of reports on MDR
organism carriage in refugees admitted into European hospitals.
Syrian refugee patients screened in Europe have shown higher
rates of carbapenemase-producing Enterobacteriaceae (CPEs)
compared with local populations (Kassem et al., 2017; Angeletti
et al., 2016; Ravensbergen et al., 2016; Reinheimer et al., 2016;
Heudorf et al., 2016; Tenenbaum et al., 2016; Heydari et al., 2015).
Estimates of MDR carriage within paediatric and adult populations
in these studies range from 33% to 83%, with high rates of New
Delhi metallo-beta-lactamase (NDM)-producing carbapenem-re-
sistant Enterobacteriaceae (CRE), A. baumannii, and ESBL-producing
Enterobacteriaceae (Rafei et al., 2014; Kassem et al., 2017; Angelettiet al., 2016; Ravensbergen et al., 2016; Reinheimer et al., 2016;
Heudorf et al., 2016; Tenenbaum et al., 2016). This is significantly
greater than the background carriage rates of the local populations
such as in Germany, where colonization with MDR Gram-negatives
was identified in 60.8% of a refugee population (of whom 18.6%
were Syrian) screened on admission to hospital versus 16.8% in the
general population (Ravensbergen et al., 2016).
Comparative data from the European Antimicrobial Resistance
Surveillance Network (EARS-Net) showed rates of resistance for seven
specific pathogens in 2015.28 Penicillin non-susceptibility in S. pneumo-
niae ranged from 0.6% in Belgium to 39% in Romania. Carbapenem
resistance was 0.1%, 8.1%, and 17.8% in E. coli, K. pneumoniae, and P.
aeruginosa, respectively, with the highest rate of 93.5% seen in
Acinetobacter sp in Greece. Polymyxin resistance was 0.8%, 4%, and
8.8% in P. aeruginosa, Acinetobacter sp, and K. pneumoniae,
respectively. Most K. pneumoniae isolates with combined polymyx-
in and carbapenem resistance were reported from Greece and Italy.
MRSA rates ranged from 0% in Iceland to 57% in Romania.
Conclusions
This review of evidence of AMR inside Syria and in countries
hosting Syrian refugees demonstrates a paucity of rigorous studies
describing this increasingly important phenomenon. Before the
conflict, published studies inside Syria were often from single
centres and presented limited data of variable quality. Since the
onset of the conflict, no studies have described the prevalence of
AMR in those with injuries within Syria. However, evidence from
neighbouring countries suggests that this is an increasing
phenomenon. It is important to address this research and reporting
32 A. Abbara et al. / International Journal of Infectious Diseases 75 (2018) 26–33gap, as defining the current extent of AMR among Syrians will help
to inform interventions that address the drivers of AMR in this
population. This is particularly relevant given the population
movements that have resulted from the conflict and the likelihood
of ongoing challenges in addressing this issue which is of global
importance. However, there are barriers to filling this evidence gap
due to a combination of factors relating to the complex
humanitarian situation inside Syria and the overwhelmed health
systems in neighbouring countries. Collaboration and innovations
are required to address this issue, which is of global importance.
The second part of this two-part series addresses the drivers of
AMR before and after the onset of conflict and makes recom-
mendations as to how these can be addressed.
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Appendix A
Search methodology for the review of the literature on antimicrobial
resistance in Syria pre and post the onset of conflict
Drug-resistant bacteria were defined according to the US
Centers for Disease Control and Prevention (CDC) definition as
“microorganisms, predominantly bacteria, that are resistant to oneor more classes of antimicrobial agents”; multidrug-resistant
(MDR) bacteria were defined as microorganisms that are resistant
to one or more agents in at least three separate classes, methicillin-
resistant Staphylococcus aureus (MRSA), or an extended-spectrum
beta-lactamase (ESBL)-producing organism.
Information about antimicrobial resistance in Syria or amongst
Syrian refugees was collected. A detailed scoping review was
performed to summarize the available literature on AMR affecting
Syrians pre and post conflict. This aimed to identify the key
emerging themes and current concepts, and to highlight gaps in
current evidence on AMR in Syria. MEDLINE, PubMed, Embase, and
the World Health Organization (WHO) Global Health Library were
searched using the terms ‘Syria’ and ‘antibiotic resistance’. The
grey literature was searched using other search engines with the
following additional terms: ‘Syria’, ‘refugee’, ‘antimicrobial resis-
tance’, ‘screening’, ‘war-injury’. Only articles in English were
included. The journal of the Syrian Clinical Laboratory Association
was also searched. This was included to ensure that relevant
literature was not missed; however the peer review process for this
journal is unknown. Any identified references within the literature
that were deemed relevant were also included in the final review.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at https://doi.org/10.1016/j.ijid.2018.06.010.
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